These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38898688)
21. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593 [TBL] [Abstract][Full Text] [Related]
22. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre. Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085 [TBL] [Abstract][Full Text] [Related]
23. The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity. Carles A; Trigo-Gonzalez G; Cao Q; Cheng SG; Moksa M; Bilenky M; Huntsman DG; Morin GB; Hirst M Cancer Res; 2020 Sep; 80(17):3480-3491. PubMed ID: 32641414 [TBL] [Abstract][Full Text] [Related]
24. Composite Serous Borderline Tumor and Adult Granulosa Cell Tumor-like Area: Is it a True Neoplastic AGCT or Tumor-like Proliferation? Yu J; Nie X Int J Gynecol Pathol; 2017 May; 36(3):265-269. PubMed ID: 27648785 [TBL] [Abstract][Full Text] [Related]
25. Composite FOXL2 Mutation-positive Adult Granulosa Cell Tumor and Serous Borderline Tumor of the Ovary. Guerrieri C; Hudacko R; Anderson P Int J Gynecol Pathol; 2023 Sep; 42(5):500-507. PubMed ID: 36044294 [TBL] [Abstract][Full Text] [Related]
27. Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing. Choi YJ; Ho J; Lee A; Hur SY; Park HC; Park JS; Chung YJ; Lee SH Pathol Res Pract; 2018 Aug; 214(8):1231-1233. PubMed ID: 29937308 [TBL] [Abstract][Full Text] [Related]
29. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit. Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373 [TBL] [Abstract][Full Text] [Related]
30. Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. Singh N; Gilks CB; Huntsman DG; Smith JH; Coutts M; Ganesan R; McCluggage WG Histopathology; 2014 Apr; 64(5):626-32. PubMed ID: 24138090 [TBL] [Abstract][Full Text] [Related]
31. The FOXL2 mutation (c.402C>G) in adult-type ovarian granulosa cell tumors of three Japanese patients: clinical report and review of the literature. Takahashi A; Kimura F; Yamanaka A; Takebayashi A; Kita N; Takahashi K; Murakami T Tohoku J Exp Med; 2013 Dec; 231(4):243-50. PubMed ID: 24257635 [TBL] [Abstract][Full Text] [Related]
32. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Kommoss S; Gilks CB; Penzel R; Herpel E; Mackenzie R; Huntsman D; Schirmacher P; Anglesio M; Schmidt D; Kommoss F Histopathology; 2014 Feb; 64(3):380-8. PubMed ID: 24192202 [TBL] [Abstract][Full Text] [Related]
33. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968 [TBL] [Abstract][Full Text] [Related]
34. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2. Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732 [TBL] [Abstract][Full Text] [Related]
36. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555 [TBL] [Abstract][Full Text] [Related]
37. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer. Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449 [TBL] [Abstract][Full Text] [Related]
38. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279 [TBL] [Abstract][Full Text] [Related]
39. FOXL2 Mutation Status in Granulosa Theca Cell Tumors of the Ovary. Nolan A; Joseph NM; Sangoi AR; Rabban J; Zaloudek C; Garg K Int J Gynecol Pathol; 2017 Nov; 36(6):568-574. PubMed ID: 28319575 [TBL] [Abstract][Full Text] [Related]
40. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance. Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]